MedTrace Logo

Low-Dose Weekly vs High-Dose Cisplatin

NCT03649048 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-31

No results posted yet for this study

Summary

This study is a prospective open-label randomized clinical trial. Following informed consent eligible LASCCHN patients (n=100) planned for CRT will be stratified by tumor p16 status and then randomized in a 1:1 fashion to either concurrent HD cisplatin or concurrent weekly LD cisplatin.

Conditions

  • Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

High-Dose Cisplatin

Intravenous administration of High-Dose Cisplatin

DRUG

Low-Dose Cisplatin

Intravenous administration of Low-Dose Cisplatin

RADIATION

Radiotherapy

Participating centres are to follow their local radiation treatment planning and delivery techniques.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Sara Kuruvilla, MD · London Health Sciences Centre, London Regional Cancer Program

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-05
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649048 on ClinicalTrials.gov